New York State Common Retirement Fund lowered its stake in shares of Quidel Co. (NASDAQ:QDEL) by 0.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 747,998 shares of the company’s stock after selling 3,800 shares during the period. New York State Common Retirement Fund owned approximately 1.80% of Quidel worth $56,122,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of QDEL. CFM Wealth Partners LLC bought a new position in shares of Quidel during the 4th quarter valued at about $26,000. Nisa Investment Advisors LLC lifted its holdings in shares of Quidel by 300.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 760 shares of the company’s stock valued at $47,000 after purchasing an additional 570 shares in the last quarter. Exchange Traded Concepts LLC bought a new position in shares of Quidel during the 4th quarter valued at about $84,000. Russell Investments Group Ltd. bought a new position in shares of Quidel during the 3rd quarter valued at about $110,000. Finally, Strs Ohio lifted its holdings in shares of Quidel by 66.7% during the 4th quarter. Strs Ohio now owns 1,500 shares of the company’s stock valued at $112,000 after purchasing an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 89.68% of the company’s stock.
Several equities analysts have recently weighed in on QDEL shares. TheStreet upgraded Quidel from a “c+” rating to a “b” rating in a report on Friday, November 1st. ValuEngine cut Quidel from a “hold” rating to a “sell” rating in a report on Tuesday, February 4th. Zacks Investment Research upgraded Quidel from a “sell” rating to a “hold” rating in a report on Wednesday, December 25th. BidaskClub cut Quidel from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Canaccord Genuity reiterated a “buy” rating and set a $75.00 price objective (up previously from $70.00) on shares of Quidel in a report on Sunday, November 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Quidel currently has a consensus rating of “Buy” and a consensus target price of $74.00.
Quidel (NASDAQ:QDEL) last released its earnings results on Wednesday, February 12th. The company reported $1.00 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.18. The firm had revenue of $152.20 million for the quarter, compared to analysts’ expectations of $148.00 million. Quidel had a return on equity of 22.48% and a net margin of 14.51%. The business’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.80 EPS. On average, equities research analysts forecast that Quidel Co. will post 2.55 EPS for the current year.
In other Quidel news, SVP Ratan S. Borkar sold 4,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $70.00, for a total value of $329,000.00. Following the sale, the senior vice president now owns 14,004 shares in the company, valued at approximately $980,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Edward Keith Russell sold 15,974 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $68.73, for a total value of $1,097,893.02. Following the completion of the sale, the senior vice president now owns 25,280 shares in the company, valued at approximately $1,737,494.40. The disclosure for this sale can be found here. Insiders sold a total of 43,625 shares of company stock worth $3,054,807 in the last 90 days. Company insiders own 14.10% of the company’s stock.
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology. The company offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye.
See Also: How to Invest in an Index Fund
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.